Aclaris Therapeutics And 2 Other US Penny Stocks To Watch

As the United States market continues its upward trend, with the S&P 500 extending its winning streak and Bitcoin reaching record highs, investors are looking for opportunities beyond the well-known giants. Penny stocks, often representing smaller or newer companies, remain a relevant investment area despite their somewhat outdated name. These stocks can offer surprising value and stability when backed by solid financial foundations.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.8368	$5.81M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$143.63M	★★★★★★
So-Young International (NasdaqGM:SY)	$1.25	$84.67M	★★★★☆☆
Better Choice (NYSEAM:BTTR)	$1.7017	$3.25M	★★★★★★
Puma Biotechnology (NasdaqGS:PBYI)	$2.90	$139.41M	★★★★★★
RLX Technology (NYSE:RLX)	$1.78	$2.31B	★★★★★★
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.8694	$76.61M	★★★★★☆
PHX Minerals (NYSE:PHX)	$3.74	$138.68M	★★★★★☆

Click here to see the full list of 740 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Aclaris Therapeutics (NasdaqGS:ACRS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune-inflammatory diseases in the United States, with a market cap of $282.87 million.

Operations: The company's revenue is derived from two main segments: Therapeutics, generating $24.59 million, and Contract Research, contributing $17.04 million.

Market Cap: $282.87M

Aclaris Therapeutics, Inc. has recently secured an exclusive license agreement with Biosion, Inc. for promising antibody therapies, potentially enhancing its pipeline in immune-inflammatory diseases. Despite being unprofitable with declining revenues of US$4.35 million in the latest quarter, Aclaris has significantly reduced its net loss and maintains a solid cash position with no debt and assets covering liabilities comfortably. The company bolstered its leadership team with experienced hires from major pharmaceutical firms, which may support future strategic initiatives. However, high share price volatility and projected earnings decline remain concerns for investors considering this penny stock.

• Navigate through the intricacies of Aclaris Therapeutics with our comprehensive balance sheet health report here.
• Evaluate Aclaris Therapeutics' prospects by accessing our earnings growth report.

Allot (NasdaqGS:ALLT)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Allot Ltd. develops, sells, and markets security and network intelligence solutions for mobile, fixed, and cloud service providers and enterprises globally, with a market cap of $149.04 million.

Operations: The company has not reported any specific revenue segments.

Market Cap: $149.04M

Allot Ltd. has shown improvement in its financials, reporting a reduced net loss of US$0.24 million for Q3 2024 compared to US$12.36 million a year ago, with sales slightly increasing to US$23.24 million. Despite being unprofitable and experiencing shareholder dilution, the company maintains more cash than debt and a sufficient cash runway exceeding three years based on current free cash flow. Recent developments include a strategic partnership with Portugal's MEO for deploying Allot HomeSecure services, which could enhance revenue streams through subscription models despite ongoing challenges in profitability and increased debt levels over time.

• Click here to discover the nuances of Allot with our detailed analytical financial health report.
• Assess Allot's future earnings estimates with our detailed growth reports.

SmartRent (NYSE:SMRT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: SmartRent, Inc. is an enterprise real estate technology company that offers management software and applications to rental property stakeholders globally, with a market cap of approximately $285 million.

Operations: The company generates revenue primarily from its Electronic Security Devices segment, totaling $199.77 million.

Market Cap: $285M

SmartRent, Inc. remains unprofitable with a net loss of US$9.92 million for Q3 2024, but it has reduced losses over the past five years by 2.9% annually and maintains a strong cash position with no debt. Recent initiatives include launching maintenance Dashboards to enhance operational efficiency and introducing Alloy Fusion, an integrated smart home hub. Despite trading significantly below its estimated fair value, SmartRent's management team lacks experience with an average tenure of 1.8 years, although recent leadership changes aim to strengthen revenue growth and customer relationships in the proptech sector.

• Unlock comprehensive insights into our analysis of SmartRent stock in this financial health report.
• Gain insights into SmartRent's outlook and expected performance with our report on the company's earnings estimates.

Seize The Opportunity

• Unlock more gems! Our US Penny Stocks screener has unearthed 737 more companies for you to explore.Click here to unveil our expertly curated list of 740 US Penny Stocks.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com